Investors should monitor upcoming FDA guidance on accelerated approval for SGT-003 and initial clinical readouts from FALCON and ARTEMIS trials in H2 2026. The capital raise eliminates near-term dilution risk and supports value-inflection milestones.
SLDB drugs
SLDB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 20 $7.03entry
- T+1 · 8mo ago +1.56%α +0.46% · $7.14
- T+5 · 8mo ago +1.14%α +3.29% · $7.11
- T+20 · 7mo ago +20.77%α +11.45% · $8.49
- T+60 · 5mo ago +4.69%α −9.73% · $7.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Solid Biosciences reported financial results for Q4 and full year 2025, highlighted by strong pipeline progress across its gene therapy programs, including positive interim Phase 1/2 data for SGT-003 in Duchenne, first patient dosed in the FALCON trial for SGT-212 in Friedreich’s ataxia, and upcoming trials for SGT-501 in CPVT. The company also completed a $240 million private placement, extending its cash runway into H1 2028.
Key Financial Metrics
Key Facts
- Positive interim Phase 1/2 INSPIRE DUCHENNE data showed robust microdystrophin expression, restoration of DAPC components, and stabilization of cardiac function.
- First participant dosed in Phase 1b FALCON trial for SGT-212 in Friedreich’s ataxia; well tolerated with no treatment-related adverse events.
- Clinical sites activated for Phase 1b ARTEMIS trial of SGT-501 in CPVT; first dosing expected in Q2 2026.
- Company aligned with FDA on Phase 3 IMPACT DUCHENNE trial design; first dosing expected in April 2026.
- Completed $240 million private placement; combined with $187.9M cash at year-end, extends runway into H1 2028.
- R&D expenses increased to $140.3M in 2025 from $96.4M in 2024, reflecting advancing clinical programs.
- Net loss widened to $174.3M in 2025 from $124.7M in 2024, primarily due to increased R&D spending.
Financial Impact
Cash position strengthened by $240M private placement; total available funds now support operations into mid-2028. R&D spend increased 45% YoY to $140.3M, signaling aggressive pipeline advancement.
Risk Factors
- Clinical trial delays or safety issues could derail development timelines.
- Interim data may not translate into durable or statistically significant results in later stages.
- High cash burn rate requires continued successful execution to maintain runway through pivotal readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259444 |
Track record
14 reports on SLDB
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.62% at T+5 after the May 12, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
- Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
- May 12, 202626w ago Press Release Bearish 6/10 Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
- May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
- Apr 23, 202629w ago DEFA14A Neutral 3/10 Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
- Apr 10, 202631w ago 8-K Neutral 2/10 Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
- Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Viewing Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers